Case Report: Efficacy of Rituximab in a Patient With Familial Mediterranean Fever and Multiple Sclerosis.
case report
familal mediterranean fever
hepatotoxicity
multiple sclerosis
rituximab
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
08
2020
accepted:
04
12
2020
entrez:
15
2
2021
pubmed:
16
2
2021
medline:
16
2
2021
Statut:
epublish
Résumé
Familial Mediterranean Fever (FMF) is a genetic autoinflammatory disease characterized by recurrent episodes of fever and serositis caused by mutations in the MEFV gene, while Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the CNS with genetic and environmental etiology. The two diseases rarely occur in association with relevant implications for clinical management and drug choice. In this paper, we present the case of a 53-year-old male with an autosomal dominant FMF since childhood who presented acute paresthesia at the right part of the body. He performed a brain and spinal cord MRI, which showed multiple brain lesions and a gd-enhancing lesion in the cervical spinal cord, and then received a diagnosis of MS. He then started Interferonβ-1a which was effective but not tolerated and caused hepatotoxicity, and then shifted to Rituximab with 3-month clinical and neuroradiological efficacy.
Identifiants
pubmed: 33584496
doi: 10.3389/fneur.2020.591395
pmc: PMC7874168
doi:
Types de publication
Case Reports
Langues
eng
Pagination
591395Informations de copyright
Copyright © 2021 Pozzato, Micaglio, Starvaggi Cucuzza, Cagol, Galimberti, Calandrella, Cinnante, Pappone, Zanussi, Meola, Scarpini, Bresolin and Martinelli Boneschi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurology. 2014 Apr 15;82(15):1302-6
pubmed: 24634453
Ital J Pediatr. 2020 Jan 15;46(1):7
pubmed: 31941537
Clin Rheumatol. 2019 Feb;38(2):577-581
pubmed: 30062447
Case Rep Nephrol Urol. 2012 Jul;2(2):92-101
pubmed: 23197963
Genes Immun. 2004 Sep;5(6):493-504
pubmed: 15269719
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Iran J Med Sci. 2014 Jan;39(1):2-10
pubmed: 24453388
Med Hypotheses. 2012 Jun;78(6):717-20
pubmed: 22406096
Acta Reumatol Port. 2014 Oct-Dec;39(4):342-4
pubmed: 25005448
Clin Exp Rheumatol. 2006 Sep-Oct;24(5 Suppl 42):S120-2
pubmed: 17067442
P T. 2012 Mar;37(3):175-84
pubmed: 22605909
Neurol Sci. 2015 May;36(5):811-2
pubmed: 25116260
Neurology. 2016 Nov 15;87(20):2074-2081
pubmed: 27760868
Nat Genet. 1997 Sep;17(1):25-31
pubmed: 9288094
Rheumatology (Oxford). 2020 Jun 1;59(6):1372-1380
pubmed: 31598713
Drugs. 2011 Oct 1;71(14):1865-91
pubmed: 21942977
Eur J Neurol. 2011 Sep;18(9):1146-50
pubmed: 21299735
Rheumatol Int. 2012 Apr;32(4):895-908
pubmed: 21229358
Nat Genet. 2015 Oct;47(10):1107-1113
pubmed: 26343388
BMC Med Genet. 2015 Jul 28;16:55
pubmed: 26212423
J Immunol. 2017 Jun 15;198(12):4553-4560
pubmed: 28583987
J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):126-9
pubmed: 25716934